AstraZeneca's late-stage trial testing Imfinzi, on its own or with tremelimumab, against lung cancer should yield results in the second half of 2018, according to the drugmaker.
Lung cancer study to report in second half of 2018
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.